Table 2.
Secondary efficacy variables in the studied groups
| Efficacy variables | BTX-A
|
rTMS arm
|
|||
|---|---|---|---|---|---|
| Mean (SD) | P-value (comparison with baseline) | Mean (SD) | P-value (comparison with baseline) | ||
| 25-Item Henry Ford Hospital Headache Disability Inventory (HDI) | Baseline | 75.87 (4.31) | 74.93 (3.25) | ||
| Week 4 | 40.21 (5.41) | 0.002 | 39.57 (4.72) | 0.01 | |
| Week 8 | 36.76 (8.47) | 0.001 | 42.89 (4.54) | 0.04 | |
| Week 12 | 34.80 (8.13) | 0.001 | 69.31 (5.61) | 0.06 | |
| HIT-6 | Baseline | 63.53 (4.55) | 63.41 (4.28) | ||
| Week 4 | 44.41 (5.62) | 0.03 | 44.29 (5.37) | 0.03 | |
| Week 8 | 42.86 (4.55) | 0.01 | 47.47 (7.35) | 0.04 | |
| Week 12 | 44.27 (5.18) | 0.02 | 57.33 (4.77) | 0.21 | |
Abbreviations: BTX-A, botulinum toxin-A; HDI, Headache Disability Inventory; HIT-6, Headache Impact Test; rTMS, repetitive transcranial magnetic stimulation; SD, standard deviation.